Mumps in Poland in 2019.


Journal

Przeglad epidemiologiczny
ISSN: 0033-2100
Titre abrégé: Przegl Epidemiol
Pays: Poland
ID NLM: 0413725

Informations de publication

Date de publication:
2021
Historique:
entrez: 26 10 2021
pubmed: 27 10 2021
medline: 28 10 2021
Statut: ppublish

Résumé

Mumps is a highly infectious viral disease, the source of infection is an infected person. In 2003, compulsory vaccination against mumps was introduced in Poland, carried out according to a two-dose schedule. The combined MMR vaccine (against measles, mumps and rubella) is used as part of the Protective Vaccination Program (PVP). Mumps vaccination has led to a significant reduction in the incidence of mumps in Poland. The aim of the study was to evaluate the epidemiological indicators of mumps in Poland in 2019 compared to previous years. The analysis of the epidemiological situation of mumps in Poland in 2019 was based on the interpretation of data from the bulletin "Infectious diseases and poisonings in Poland in 2019" and "Vaccinations in Poland in 2019". In 2019, 1,338 mumps cases were registered in Poland. The total incidence was 3.5 per 100,000 inhabitants and was lower compared to 2018. The highest incidence 4.6 per 100,000 inhabitants were registered in the Opolskie Voivodeship and the lowest - 2.5 in the Podkarpackie Voivodeship. The incidence was the highest among 6-year-olds and amounted to 32.3/100,000. Comparing the differences between the sexes, the incidence of men (4.1/100,000) was higher than that of women (2.9). In 2019, 22 patients were hospitalized due to mumps in Poland, which was less than in 2018 (28). The level of mumps vaccination in children at 3 years of age was lower by 0.3% compared to 2018 and amounted to 92.6% in Poland. Maintaining a high percentage of children vaccinated against mumps will provide sustaining decline in cases of mumps in the coming years.

Sections du résumé

BACKGROUND BACKGROUND
Mumps is a highly infectious viral disease, the source of infection is an infected person. In 2003, compulsory vaccination against mumps was introduced in Poland, carried out according to a two-dose schedule. The combined MMR vaccine (against measles, mumps and rubella) is used as part of the Protective Vaccination Program (PVP). Mumps vaccination has led to a significant reduction in the incidence of mumps in Poland.
AIM OBJECTIVE
The aim of the study was to evaluate the epidemiological indicators of mumps in Poland in 2019 compared to previous years.
METHODS METHODS
The analysis of the epidemiological situation of mumps in Poland in 2019 was based on the interpretation of data from the bulletin "Infectious diseases and poisonings in Poland in 2019" and "Vaccinations in Poland in 2019".
RESULTS RESULTS
In 2019, 1,338 mumps cases were registered in Poland. The total incidence was 3.5 per 100,000 inhabitants and was lower compared to 2018. The highest incidence 4.6 per 100,000 inhabitants were registered in the Opolskie Voivodeship and the lowest - 2.5 in the Podkarpackie Voivodeship. The incidence was the highest among 6-year-olds and amounted to 32.3/100,000. Comparing the differences between the sexes, the incidence of men (4.1/100,000) was higher than that of women (2.9). In 2019, 22 patients were hospitalized due to mumps in Poland, which was less than in 2018 (28). The level of mumps vaccination in children at 3 years of age was lower by 0.3% compared to 2018 and amounted to 92.6% in Poland.
CONCLUSIONS CONCLUSIONS
Maintaining a high percentage of children vaccinated against mumps will provide sustaining decline in cases of mumps in the coming years.

Identifiants

pubmed: 34696560
doi: 10.32394/pe.75.21
doi:

Substances chimiques

Measles-Mumps-Rubella Vaccine 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

229-234

Informations de copyright

© National Institute of Public Health NIH – National Research Institute.

Auteurs

Joanna Bogusz (J)

National Institute of Public Health NIH - National Research Institute, Department of Epidemiology of Infectious Diseases and Surveillance.

Aneta Rosolak (A)

National Institute of Public Health NIH - National Research Institute, Department of Epidemiology of Infectious Diseases and Surveillance.

Iwona Paradowska-Stankiewicz (I)

National Institute of Public Health NIH - National Research Institute, Department of Epidemiology of Infectious Diseases and Surveillance.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH